Copyright ©The Author(s) 2019.
World J Gastroenterol. Aug 7, 2019; 25(29): 3897-3919
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.3897
Table 4 Recommended preferred treatment regimens for hepatitis C virus GT2 infection
Recommendation categoryTreatment option(s)Treatment regimen
PreferredSOF + DCV ± RBVSOF + DCV for 12 wk in noncirrhotics
In decompensated cirrhosis and previous failures:
SOF + DCV + RBV for 12 wk
SOF + RBVSOF + RBV for 12 wk in noncirrhotics
To be extended to 24 wk in cirrhotics and treatment failures (Data are not available for patients with decompensated cirrhosis.)
Should be considered as an alternative regimen when DCV is not available
Not recommendedDue to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.